Novel pathways for glycaemic control in type 2 diabetes: Focus on bile acid modulation

Diabetes, Obesity and Metabolism

Volumn 10, Issue 11, 2008, Pages 1004-1011

  Brinton, Eliot A ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Cardiovascular Genetics   (United States)

Author keywords

Bile acid; Bile acid sequestrant; Colesevelam HCl; Glycaemic control; Type 2 diabetes

Indexed keywords

ACARBOSE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BILE ACID; BILE ACID SEQUESTRANT; COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; DIGITALIS; EZETIMIBE; FENOFIBRATE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; METHOTREXATE; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PENICILLIN G; PLACEBO; PRAVASTATIN; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; THYROID HORMONE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

BILE ACID METABOLISM; BILE ACID SYNTHESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ENTEROHEPATIC CIRCULATION; GASTROINTESTINAL DISEASE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSULIN METABOLISM; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 54249157393     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00903.x     Document Type: Review

References (60)

1. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884-1890.
2. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-932.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
4. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
5. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998; 21: 1167-1172.
6. CDC. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta: US Department of Health and Human Services, CDC, 2005.
7. Buse JB. Progressive use of medical therapies in type 2 diabetes. Diabetes Spectrum 2000; 13: 211-226.
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
11. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
12. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
13. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
14. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
15. American Diabetes Association. Standards of medical care in diabetes -2007. Diabetes Care 2007; 30: S4-S41.
16. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006; 25: 1419-1425.
17. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
18. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
19. Braunlin W, Zhorov E, Smisek D. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints 2000; 41: 708-709.
20. Makishima M, Okamoto AY, Repa JJ et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365.
21. Kawamata Y, Fujii R, Hosoya M et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-9440.
22. Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem 2001; 276: 15816-15822.
23. Duran-Sandoval D, Mautino G, Martin G et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53: 890-898.
24. Cariou B, van Harmelen K, Duran-Sandoval D et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006; 281: 11039-11049.
25. Cariou B, van Harmelen K, Duran-Sandoval D et al. Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 2005; 579: 4076-4080.
26. Duran-Sandoval D, Cariou B, Percevault F et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005; 280: 29971-29979.
27. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-1109.
28. Stayrook KR, Bramlett KS, Savkur RS et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005; 146: 984-991.
29. Yamagata K, Daitoku H, Shimamoto Y et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004; 279: 23158-23165.
30. Zhang Y, Lee FY, Barrera G et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 1006-1011.
31. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003; 278: 39124-39132.
32. Kobayashi M, Ikegami H, Fujisawa T et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007; 56: 239-247.
33. Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489.
34. Koide M, Okabayashi Y, Otsuki M. Role of endogenous bile on basal and postprandial CCK release in humans. Dig Dis Sci 1993; 38: 1284-1290.
35. Gomez G, Upp JR Jr, Lluis F et al. Regulation of the release of cholecystokinin by bile salts in dogs and humans. Gastroenterology 1988; 94: 1036-1046.
36. Kogire M, Gomez G, Uchida T, Ishizuka J, Greeley GH Jr, Thompson JC. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas 1992; 7: 15-20.
37. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-390.
38. Suzuki T, Oba K, Igari Y et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007; 74: 338-343.
39. Bays HE, Goldberg RB, Truitt K et al. Addition of colesevelam HCl to patients with type 2 diabetes mellitus inadequately controlled on a metformin-based therapy improves glycemic control. 16th Annual American Association of Clinical Endocrinologists Meeting and Clinical Congress. Seattle, Washington, 2007.
40. Fonseca V, Rosenstock J, Truitt K et al. Colesevelam HCl added to sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes mellitus improves glycemic control. 16th Annual American Association of Clinical Endocrinologists Meeting and Clinical Congress. Seattle, Washington, 2007.
41. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121: 416-422.
42. Goldberg RB, Truitt K. Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy. American Heart Association Scientific Sessions. Chicago, IL, 2006.
43. Suzuki T, Oba K, Futami S et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: A case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006; 73: 277-284.
44. Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007; 54: 53-58.
45. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29: 74-83.
46. Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp 1975; 18: 276-284.
47. Duntsch G. [Colestipol by hypercholesteremia in diabetics]. Fortschr Med 1977; 95: 1492-1496.
48. Tonolo G, Melis MG, Formato M et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-987.
49. Melian EB, Plosker GL. Colesevelam. Am J Cardiovasc Drugs 2001; 1: 141-146; discussion 147-148.
50. Kwiterovich P. A review of lipid-modifying drugs used alone and in combination. Adv Stud Med 2005; 5: 475-491.
51. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. South Med J 2006; 99: 257-273.
52. Bays H, Dujovne C. Colesevelam HCl: A non-systemic lipid-altering drug. Expert Opin Pharmacother 2003; 4: 779-790.
53. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007; 23: 1673-1684.
54. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67: 1383-1392.
55. Thomson AB, Keelan M. Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. Digestion 1987; 38: 160-170.
56. Forman B, Van Citters G, Lin M, Jones M. Colesevelam HCl improves insulin sensitivity in mice by establishing a futile cycle of cholesterol flux and fatty acid oxidation. 4th Annual World Congress on the Insulin Resistance Syndrome. Las Vegas, NV, 2006.
57. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998; 19: 355-371.
58. Farmer JA, Gotto AM Jr. Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Saf 1994; 11: 301-309.
59. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000; 14: 681-690.
60. Deushi M, Nomura M, Kawakami A et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-5670.